



Oifig an Stiúrthóra Náisiúnta
Géaroibríochtaí

Aonad 4A, Áras Dargan, An Ceantar Theas,
An Bóthar Míleata, Cill Mhaighneann, Baile
Átha Cliath 8, D08 NN9V

Office of the National Director
Acute Operations

Unit 4a, the Dargan Building, Heuston
South Quarter, Military Road,
Kilmainham, Dublin 8, D08 NN9V

www.hse.ie
@hselive

t 01 795 9972
e acutehospitals@hse.ie

Deputy Colm Burke
Dáil Éireann
Leinster House
Dublin 2

7th July 2023

PQ 33547/23 - To ask the Minister for Health the specific drugs that have been considered to date by the rare diseases technology review committee of the HSE, in tabular form; the outcomes of these decisions; the timelines for each from EMA licence to availability to Irish patients; and if he will make a statement on the matter. -Colm Burke

Dear Deputy Burke,

The Health Service Executive has been requested to reply directly to you in the context of the above parliamentary question, which you submitted to the Minister for Health for response.

In order to respond to your Parliamentary Question, Acute Operations contacted the Rare Diseases Technology Review Committee (RDTRC).

In informing your PQ, the RDTRC advised:

The HSE Drugs Group may request Patient and Clinician Engagement input for a drug via the Rare Diseases Technology Review Committee (RDTRC) to assist the group in making a recommendation to the HSE Executive Management Team regarding reimbursement of said drug.

The RDTRC review all pertinent data available and facilitate Patient and Clinician Engagement. A statement is then issued from the RDTRC to the HSE Drugs Group for final decision making.

The RDTRC supplied the information on the included Excel file.

The file displays the drug considered, EMA License Data, the date the HSE Drugs Group requests RDTRC Engagement, the date the RDTRC delivers its statement to the HSE Drugs Group and the outcome.



I trust this is of assistance to you.

Yours sincerely,

A handwritten signature in blue ink, appearing to be 'Nessa Lynch', written over a horizontal line. The signature is highly stylized and cursive.

Nessa Lynch
General Manager
Acute Operations